Immunovia, Inc. achieves Clinical Laboratory Licensure from Rhode Island Dept of Health making IMMray™ PanCan-d test available in 46 US states

LUND, Sweden, Might 17, 2022 /PRNewswire/ — The Rhode Island Division of Well being has granted Immunovia, Inc., the US subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), Medical Laboratory licensure, permitting physicians in Rhode Island to order the IMMray™ PanCan-d take a look at for his or her sufferers.

“Receiving licensure in Rhode Island now permits us to supply IMMray™ PanCan-d in 46 states. We count on extra state licensures to observe, as we work to make IMMray™ PanCan-d accessible to sufferers throughout the US who’re in danger for pancreatic most cancers,” says Jeff Borcherding, Chief Govt Officer of Immunovia, Inc., the US subsidiary of Immunovia AB.

For extra info, please contact:
Philipp Mathieu
Appearing CEO and President
E mail: [email protected]

Tobias Bülow
Senior Director Investor Relations and Company Communications
E mail: [email protected]
Tel: +46 736 36 35 74

The data was submitted for publication on March 17, 2022, at 08:30 am CET.

About Immunovia

Immunovia AB is a diagnostic firm with the imaginative and prescient to revolutionize blood-based diagnos­tics and improve survival charges for sufferers with most cancers.

Our first product, IMMray™ PanCan-d is the one blood take a look at presently obtainable particularly for the early detection of pancreatic most cancers. The take a look at has unmatched scientific efficiency. Commercializa­tion of IMMray™ PanCan-d began in August 2021 within the USA and IMMray™ PanCan-d is obtainable as a laboratory developed take a look at (LDT) solely by Immunovia, Inc. For extra info see: www.immunoviainc.com.

Immunovia collaborates and engages with healthcare suppliers, main consultants and affected person advert­vocacy teams globally to make this take a look at obtainable to all high-risk pancreatic most cancers teams.

The USA, the primary market through which IMMray™ PanCan-d is commercially obtainable, is the world’s largest marketplace for the detection of pancreatic most cancers with an estimated worth of greater than USD 4 billion yearly.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For extra info, please go to www.immunovia.com.

This info was delivered to you by Cision http://information.cision.com

https://information.cision.com/immunovia-ab/r/immunovia–inc–achieves-clinical-laboratory-licensure-from-rhode-island-dept-of-health-making-immra,c3567971

The next recordsdata can be found for obtain:

SOURCE Immunovia AB